Arrowhead Pharmaceuticals Unveils Data From Two Studies

By Michael Dabaie

Arrowhead Pharmaceuticals Inc. (ARWR) Friday unveiled data from a pair of studies to be presented at the annual meeting of the American Association for the Study of Liver Disease.

The company is presenting data from a Phase 1 study of ARO-AAT, its RNA interference therapeutic to treat a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

"ARO-AAT at single- and multiple-doses produced robust and consistent reductions in serum AAT levels," the company said. Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible.

The company also unveiled preliminary clinical data from a Phase 1/2 study of ARO-HBV, a therapeutic candidate being developed as a potential treatment for patients with chronic hepatitis B virus infection.

ARO-HBV administered subcutaneously appears to be well-tolerated at single or multiple monthly doses up to 400 mg. Strong hepatitis B surface antigen responses were observed in all hepatitis B virus patients, the company said.

Arrowhead recently entered into a license agreement with Janssen Pharmaceuticals Inc., part of Johnson & Johnson (JNJ), to develop and commercialize ARO-HBV.

Arrowhead shares were recently down 5%, to $14.57.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

November 09, 2018 13:00 ET (18:00 GMT)

Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024